Skip to ContentSkip to Navigation
How to find us drs. M. Nijland

Publications

Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study

Primary therapy and survival in patients over 70 years old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands

Borrelia burgdorferi mimicking central nervous system relapse in diffuse large B cell lymphoma

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study

Interim thymus and activation regulated chemokine versus interim F-18-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation

Late relapses in diffuse large B-cell lymphoma: where to move next?

Molecular imaging in lymphoma beyond F-18-FDG-PET: understanding the biology and its implications for diagnostics and therapy

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Read more

Press/media

Medtalks:Diffuus Grootcellig B-cellymfoom 2018